^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ProstVac (rilimogene galvacirepvec)

    i
    Associations
    News

    Trials

    Company:
    Bavarian Nordic, National Cancer Institute
    Drug class:
    Immunostimulant, KLKB1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer (NCT02933255)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    05/31/2024
    Initiation :
    04/18/2017
    Primary completion :
    06/20/2023
    Completion :
    12/01/2023
    CD4
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • ProstVac (rilimogene galvacirepvec)
    Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer (16-C-0048) (NCT02649855)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    10/31/2023
    Initiation :
    01/19/2016
    Primary completion :
    07/01/2022
    Completion :
    08/08/2024
    CD8 • IFNG • MUC1 • TNFA • CEACAM5 • CD4 • IL2 • LAMP1
    |
    docetaxel • ProstVac (rilimogene galvacirepvec)
    PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance (NCT02326805)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/19/2023
    Initiation :
    06/03/2015
    Primary completion :
    11/30/2018
    Completion :
    07/20/2022
    PD-L1 • CD8 • CD4
    |
    PD-L1 expression • CD4 positive
    |
    ProstVac (rilimogene galvacirepvec)
    Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy (NCT02153918)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/12/2018
    Initiation :
    05/31/2014
    Primary completion :
    07/28/2017
    Completion :
    01/16/2018
    CD8 • CD4 • FOXP3
    |
    ProstVac (rilimogene galvacirepvec)